Effect of deferoxamine on post-hypoxic-ischemic reperfusion injury of the newborn lamb heart

Biology of the Neonate

Volumn 75, Issue 4, 1999, Pages 239-249

  Shadid, Majidah ^b   Van Bel, Frank ^b   Steendijk, Paul ^b   Dorrepaal, Caroline A ^b   Moison, Ralph ^b   Van Der Velde, Enno T ^b   Baan, Jan ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NONE

Author keywords

End systolic pressure volume relationship; Hypoxia ischemia; Left ventricular function; Newborn lambs; Reactive oxygen species; Reperfusion injury

Indexed keywords

ASCORBIC ACID; CHELATING AGENT; DEFEROXAMINE; DEHYDROASCORBIC ACID; HYDROXYL RADICAL; IRON; MALONALDEHYDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA PRESSURE; ARTICLE; CONTROLLED STUDY; CORONARY SINUS; FEMALE; HEART EJECTION FRACTION; HEART LEFT VENTRICLE CONTRACTILITY; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEART STROKE VOLUME; INTRAVENOUS DRUG ADMINISTRATION; LAMB; MALE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; REPERFUSION INJURY; VASCULAR RESISTANCE;

EID: 0032994468     PISSN: 00063126     EISSN: None     Source Type: Journal    
DOI: 10.1159/000014101     Document Type: Article

References (41)

1. Walther FJ, Siassi B, Ramadan NA, Wu PYK: Cardiac output in newborn infants with transient myocardial dysfunction. J Pediatr 1985; 107:781-785.
2. Tsao PS, Lefer AM: Time course of endothelial dysfunction in isolated ischemic-and hypoxic-perfused rat hearts. Am J Physiol 1990;259: H1660-H1666.
3. Buckberg GD: Studies of hypoxemic/reoxygenation injury: Linkage between cardiac function and oxidant damage. J Thorac Cardiovasc Surgi 995;110:1165-1170.
4. Nakamura H, delNido P, Jimenez E, Sarin M, Feinberg H, Levitsky S: Age-related differences in cardiac susceptibility to ischemia/reperfusion injury. Cardiovasc Surg 1992; 104:165-172.
5. Gutterige JM, Richmond R, Halliwell B: Inhibition of the iron catalysed formation of hydroxyl radicals from Superoxide and lipid peroxidation by desferrioxamine. Biochem J 1979;184:469-472.
6. Williams RE, Zweier JL, Faherty JT: Treatment with deferoxamine during ischemia improves functional and metabolic recovery and reduces reperfusion-induced oxygen radical generation in rabbit hearts. Circulation 1991;83:1006-1014.
7. Bolli R, Patel BS, Zhu WX, O'Neill PG, Hartley CJ, Charlat ML, Roberts R: The iron chelator desferrioxamine attenuates postischemic ventricular dysfunction. Am J Physiol 1987;22:H1372-H1380.
8. Voogd A, Sluiter W, Van Eijk HG, Koster JF: Low molecular weight iron and the oxygen paradox in isolated rat hearts. J Clin Invest 1992; 90:2050-2055.
9. deLemos RA, Roberts RJ, Coalson JJ. deLemos JA, Null DM, Gerstmann DR: Toxic effects associated with the administration of deferoxamine in the premature baboon with hyaline membrane disease. Am J Dis Child 1990;144:915-919.
10. Sekili S, McCay P, Li XY, Zughaib M, Sun JZ, Tang L, Thornby JI, Bolli R: Direct evidence that the hydroxyl radical plays a pathogenic role in myocardial stunning in the conscious dog and demonstration that stunning can be markedly attenuated without subsequent adverse effects. Circ Res 1993;73:705-723.
11. Suga H, Sagawa K, Shoukas AA: Load independence of the instantaneous pressure-volume ratio of the canine left ventricle and effects of epinephrine and heart rate on the ratio. Circ Res 1973;32:314-322.
12. Baan J, Van Der Velde ET: Sensitivity of left ventricular end-systolic pressure volume relation to type of loading intervention in dogs. Circ Res 1988;62:1247-1258.
13. Teitel DF, Klautz RJM, Steendijk P, Van Der Velde ET, Van Bel F, Baan J: The end-systolic pressure-volume relationship in the newborn lamb: Effects of loading and inotropic interventions. Pediatr Res 1991;29: 473-482.
14. Van Der Velde ET, Burkhoff D, Steendijk P, Karsdon J, Sagawa K, Baan J: Nonlinearity and load sensitivity of the end-systolic pressure-volume relation of canine left ventricle in vitro. Circulation 1991;83: 315-327.
15. Lew WYW: Time-dependent increase in left ventricular contractility following acute volume-loading in the dogs. Circ Res 1988;63:635-647.
16. max end-diastolic volume relation in closed-chest dogs. Circ Res 1985; 56:808-815.
17. Baan J, Van Der Velde ET, De Bruin HG, Smeenk GJ, Koops J, Van Dijk AD, Temmerman D, Senden J, Buis B: Continuous measurement of the left ventricular volume in animals and humans by conductance catheter. Circulation 1984; 70:812-823.
18. Applegate RJ, Cheng CP, Little WC: Simultaneous catheter and dimension assessment of left ventricular volume in the intact animal. Circulation 1990;81:638-648.
19. Grossman W, McLaurin LP: Cardiac Catheterisation and Angiography. Philadelphia, Lea & Febiger, 1980.
20. Halliwell B, Chirico S: Lipid peroxidation: Its mechanism, measurements and significance. Am J Clin Nutr 1993;57:715S-725S.
21. Thurnham DI, Smith E, Flora PS: Concurrent liquid-chromatographic assay of retinol, α-tocopherol, β-carotene, α-carotene, lycopene, and β-cryptoxanthin in plasma, with tocopherol acetate as internal standard. Clin Chem 1988;34:377-381.
22. Lopez-Anaya A, Mayersohn M: Ascorbic and dehdroascorbic acids simultaneously quantified in biological fluids by liquid chromatography with fluorescence detection, and comparison with a colorimetric assay. Clin Chem 1987;33:1874-1878.
23. White PF, Way WL, Trevor AJ: Ketamine - Its pharmacology and therapeutic uses. Anesthesiology 1982; 56:119-136.
24. Bolli R, Patel BS, Jeroudi MO, Li XY, Triana JF, Lai EK, McCay PB: Iron-mediated radical reactions upon reperfusion contribute to myocardial stunning. Am J Physiol 1990;28:H1901-H1911.
25. Katoh S, Toyama J, Kodama I, Akita T, Abe T: Deferoxaminc, an iron chelator, reduces myocardial injury and free radical generation in isolated neonatal rabbit hearts subjected to global ischemia-reperfusion. J Mol Cell Cardiol 1992;24: 1267-1275.
26. Morita K, Ihnken K, Buckberg GD, Sherman MP, Young HH: Studies of hypoxemic/reoxygenation injury: Without aortic clamping. J Thorac Cardiovasc Surg 1995;110:1190-1199.
27. Forder JR, McClanahan TB, Gallagher KP, Hedlund BE, Hallaway PE, Shlafer M: Hemodynamic effects of intraarterial administration of deferoxamine or deferoxamine-pentafraction conjugate to conscious dogs. J Cardiovasc Pharmacol 1990;16:742-749.
28. Watanabe BI, Limm W, Suehiro A, Suehiro G, Premaratne S, McNamara JJ: Failure of deferoxamine to reduce myocardial infarct size in a primate model of ischemia-reperfusion injury. J Surg Res 1993;55: 537-542.
29. Hershko C: Control of disease by selective iron depletion: A novel therapeutic strategy utilizing iron chelators. Baillieres Clin Haematol 1994;7:965-975.
30. Van Der Vliet A, Smith D, O'Neill CA, Kaur H, Darley-Usmar V, Cross CE, Halliwell B: Interactions of peroxynitrite with human plasma and its constituents: Oxidative damage and antioxidant depletion. Biochem J 1994;303:295-301.
31. Hedlund BE, Hallaway PE: High dose systemic iron chelation attenuates reperfusion injury. Biochem Soc Trans 1993;21:340-343.
32. Laub R, Schneider YJ, Octave JN, Trouet A, Crichton RR: Cellular pharmacology of deferoxamine B and derivatives in cultured rat hepatocytes in relation to iron mobilization. Biochem Pharmacol 1985;34: 1175-1183.
33. Borg DC, Schaich KM: Prooxidant action of desferrioxaminc: Fenton-like production of hydroxyl radicals by reduced ferrioxamine. J Free Radic Biol Med 1986;2:237-243.
34. Hallaway PE, Eaton JW, Panter SS, Hedlund BE: Modulation of deferoxamine toxicity and clearance by covalent attachment to biocompatible polymers. Proc Natl Acad Sci USA 1989;86:10108-10112.
35. Turner JJO, Rice-Evans C, Davies MJ, Newman ES: Free radicals, myocytes and reperfusion injury. Biochem Soc Trans Cardiovasc Dysfunct 1990;18:1056-1059.
36. Sinaceur J, Ribiere C, Nordmann J, Nordmann R: Desferrioxamine: A scavenger of Superoxide radicals. Biochem Pharmacol 1984;33:1693-1694.
37. Hoe S, Rowley DA, Halliwell B: Reactions of ferrioxamine and desferrioxamine with the hydroxyl radical. Chem Biol Interact 1982;41:75-81.
38. Bolli R, Jeroudi MO, Patel BS: Marked reduction of free radical generation and contractile dysfunction by antioxidant therapy begun at the time of reperfusion. Circ Res 1989;65:607-622.
39. Palmer C, Roberts RL, Bero C: Deferoxamine posttreatment reduces ischemic brain injury in neonatal rats. Stroke 1994;25:1039-1045.
40. Hurn PD, Koehler RC, Blizzard KK, Traystman J: Deferoxamine reduces early metabolic failure associated with severe cerebral ischemic acidosis in dogs. Stroke 1995;26: 688-695.
41. Dorrepaal CA, Shadid M. Steendijk P, Van Der Velde ET, Van De Bor M, Baan J, Van Bel F: Effect of post-hypoxic-ischemic inhibition of nitric oxide synthesis on cerebral blood flow, metabolism and electrocortical brain activity in newborn lambs. Biol Neonate 1997;72:216-226.